{"summary": "human cytomegalovirus (HCMV) and varicella zoster virus (VZV) belong to the family of herpesviruses which cause infections usually acquired in childhood [1,2,3] despite the wide range of available drugs, effective treatment of viral infections is still limited. new compounds with potential biological activity are being sought all the time. o-2-phenyl-4H-quinazolin-3-yl)-benzoic acid 1 showed antiviral activity against both herpes simplex viruses 1 and 2 (HSV-1 and HSV-2) and vaccinia virus (EC50 = 12 g/mL) compound 2 showed antiviral activity against vaccinia virus in vivo. compound (aS)-9 exhibited higher potency for PI4KIII than its atropisomer aR (pIC50 of 8.3 vs. 6.9) and an improved selectivity range against the other lipid kinases. a series of quinazolinones substituted at C3 with a (diethoxyphosphoryl)isoxazolidine moiety 10 was synthesized. isatoic acid anhydride was first reacted with bromine and then transformed into 5-bromoanthranilic acid amide 14 according to the procedure in the literature [27,28] cyclization and dehydrohalogenation led to the formation of 6-bromo-2-vinyl-3H-quinazolin-4-one 13a, which was then used as a key intermediate in the preparation of N3-substituted derivatives 13b\u201313k via al in all cases good trans/cis diastereoselectivities were observed (in the range of 76\u201388%) and trans-isomers predominated. isoxazolidine cycloadducts were separated chromatographically on silica gel. cis-11c (62) b d 3-NO2-C6H4-CH2 92:8 trans-11d (14) a + trans-11d and cis-11d (80) b e 2-F-C6H4-CH2 90:10 trans-11e (18) a + trans-11e and cis-11e (72) b f 2-F-C6H4-CH2 90:10 trans-11f and cis-11f (96) b stituted 2-vinyl-3H-quinazolin-4-ones, trans and cis configurations of major trans-11a\u2013k and minor cis-11a\u2013k isomers were assigned taking advantage of previous observations. antiviral and Cytostatic evaluation 2.2.1. acyclovir, brivudin, zalcitabine, zanamivir, alovudine, amantadine, rimantadine, ribavirin, dextran sulfate (molecular weight 10000, DS-10000), mycophenolic acid, Hippeastrum hybrid agglutinin (HHA) and Urtica dioica agglutinin (UDA) were used as reference compounds incorporation of the bromine atom at C6 in the quinazolinone skeleton resulted in a significant increase in potency of isoxazolidine-conjugates 11b\u201311i against VZV. compared with previously described analogous conjugates 10b\u201310i having an unsubstituted quinazoline skeleton [25]. trans-11i/cis-11i (92:8) 2,4-diF-C6H3-CH2 8.7 3.2 10.5 0.3 >20 15.6 3.2 trans-11j CH3 >4 >4 20 n.d. acyclovir 1.55 1.0 39.2 3.6 >440 >350 Brivudin 0.023 0.008 31.9 16.1 >300 >300 a Effective concentration required to reduce virus plaque formation by 50%, n.d.\u2014not determined trans-11c 2-NO2-C6H4-CH2 >20 15.29 100 n.d. trans-11d 3-NO2-C6H4-CH2 10.4 0.8 11.6 2.5 100 37.0 4.3 trans-11e 4-NO2-C6H4-CH2 >20 >20 100 n.d. trans-11f/cis-11f (95:5) 2-F-C6H4-CH2 8.94 8.94 20 n.d. trans-11g 3-F-C6H4 almost all compounds 11a\u201311k showed inhibitory activity against the proliferation of tumour cell lines. they appeared to be the most cytostatic toward the human T-lymphocyte (CEM) cell line with an inhibitory effect in the 9.6\u201333 M range. 2-C6H4-CH2 26 1 33 25 24 9 30 0 trans-11e 4-NO2-C6H4-CH2 18 76 17 12 24 9 26 6 trans-11f/cis-11f (95:5) 2-F-C6H4-CH2 17 2 13 1 25 7 30 0 trans-11g 3-F-C6H4-CH2 16 2 10 0 25 7 30 0 trans-11h 4-F-C6H4-CH2 16 0 9.6 2.2 idine phosphonates having 3-nitrobenzyl (trans-11d) and 3-fluorobenzyl (trans-11g) substituents at N3 of the quinazolinone core showed the highest antiviral activity with an EC50 values in the range of 5.8\u201311.6 M. isoxazolidines having 2-nitrobenzyl (trans-11c) and 2,4-difluorobenzyl (trans-11i/cis-11i (92:8) uted derivatives 13b\u201313k via alkylation with the respective benzyl bromides, as well as with methyl or ethyl iodide [29] (Scheme 2). Scheme 2. Synthesis of 3-substituted 6-bromo-2-vinylquinazolinones 13a\u201313k. trans-11d (R = 3-NO2-C6H4-CH2), trans-11g (R = 3-F-C6H4-CH2), trans-11h (R = 4-F-C6H4-CH2), trans-11j (R = CH3), and trans-11k (R = CH3), as well as for a minor isomer cis-11a (R = H). cis-11g (72) b h 4-F-C6H4-CH2 92:8 trans-11h (12) a + trans-11h and cis-11h (82) b j CH3 94:6 trans-11j (32) a + trans-11j and cis-11j (65) b k CH3CH2 88:12 trans-11k (14) a + trans-11k and cis-11k (80) b yield of pure mixture of azolidines trans-11f/cis-11f (95:5) and trans-11i/cis-11i (92:8) were tested for inhibitory activity against a wide variety of DNA and RNA viruses. the following cell-based assays were used: human embryonic lung (HEL) cells (herpes simplex virus-1 (KOS strain), herpes simplex virus-2 (G strain), thymidine kinase deficient (acyclovir resistant) her tica dioica agglutinin (UDA) were used as reference compounds. the antiviral activity was expressed as the EC50: the compound concentration required to reduce virus plaque formation (VZV) by 50% or to reduce virus-induced cytopathogenicity by 50%. TK+ VZV Strain (07-1) Cell Morphology MCC b Cell Growth CC50 c cis-11a H >100 >100 >100 >100 n.d. trans-11b C6H5-CH2 13.5 7.1 13.6 9.1 100 42.3 0.3 trans-11c 2-NO2-C6H4-CH2 10.3 1.1 5.4 1.0 100 9.4 0.4 trans-11d 3-NO2-C6H4-CH2 8.3 1.4 5. c Cytotoxic concentrations required to reduce cell growth by 50%, n.d.\u2014not determined. the synthesized isoxazolidine phosphonates also showed marked activity against human cytomegalovirus (HCMV) -C6H4-CH2 10.5 2.2 8.94 0 100 33.0 3.5 trans-11h 4-F-C6H4-CH2 12.5 3.9 11.2 3.1 100 39.4 5.2 trans-11i/cis-11i (92:8) 2,4-diF-C6H3-CH2 9.4 0.46 9.7 1.1 >20 15.6 3.2 trans-11j CH3 >20 >100 20 n.d. trans-11k CH3CH2 > trans-11f/cis-11f (95:5) (IC50 = 13 1 M), trans-11g (IC50 = 10 0 M), trans-11h (IC50 = 9.6 2.2 M), and trans-11i/cis-11i (92:8) exhibited activity toward the CEM line higher than of 5-fluorouracil (IC50 = 18 5 M) 0 9.6 2.2 25 7 29 1 trans-11i/cis-11i (92:8) 2,4-diF-C6H3-CH2 16 1 9.8 4.8 22 6 30 0 trans-11j CH3 138 19 128 21 175 105 >250 trans-11k/cis-11k (97:3). a 50% Inhibitory concentration or compound concentration required to inhibit tumor cell proliferation by 50%, n.d.\u2014not determined. isoxazolidines have 2-nitrobenzyl (trans-11c) and 2,4-difluorobenzyl (trans-11i/cis-11i (92:8)) substituents at same position of a quinazolinone moiety appeared to be the most active toward the human cervix carcinoma cell line. their inhibitory concentration was much lower than that of the reference drugs. reovirus-1, Sindbis virus, Coxsackie virus B4, Punta Toro virus, yellow fever virus. acyclovir, brivudin, zalcitabine, zanamivir, alovudine, amantadine, rimantadine, ribavirin, dextran sulfate (molecular weight 10000, DS-10000), mycophenolic acid, hippeastrum hybrid agg compounds trans-11b, trans-11d, trans-11g, and trans-11h exhibited the lowest cytotoxicity (CC50 = 33\u201342 ). incorporation of the bromine atom at C6 in the quinazolinone skeleton resulted in a significant increase in potency of isoxazolidine-conjugates 11b\u201311i against VZV. acyclovir 1.55 1.0 39.2 3.6 >440 >350 Brivudin 0.023 0.008 31.9 16.1 >300 >300 a Effective concentration required to reduce virus plaque formation by 50%. activities of the tested compounds against both AD-169 and Davis strains were comparable (EC50 = 8.9\u201312.5 ) to that of Ganciclovir (EC50 = 16.9 and 7.7 ) used as a reference drug. c cis-11a H >100 >100 100 n.d. trans-11b C6H5-CH2 20 20 20 n.d. trans-11c 2-NO2-C6H4-CH2 10.4 0.8 11.6 2.5 100 37.0 4.3 trans-11e 4-NO2-C6H4-CH2 >20 >20 100 n.d. trans-11f/cis-11f (95:5) 2-F-C6H4-CH2 8.94 8.94 20 n cytostatic activity (IC50) causing a 50% decrease in cell proliferation was determined against murine leukemia L1210, human lymphocyte CEM, human cervix carcinoma HeLa, and immortalized human dermal microvacsular endothelial cells (HMEC-1). Almost all compounds 11a\u201311k showed inhibitory activity against the proliferation of tumour cell lines. -11b C6H5-CH2 20 2 16 3 26 7 30 0 trans-11c 2-NO2-C6H4-CH2 19 3 14 4 22 11 30 0 trans-11d 3-NO2-C6H4-CH2 26 1 33 25 24 9 30 0 trans-11e 4-NO2-C6H4-CH2 26 76 17 12 24 9 26 6 trans-11f/cis-11f (95:5) 2-F-C6H4-CH2 17 2 13 1 25 7 isoxazolidine phosphonates having 3-nitrobenzyl (trans-11d) and 3-fluorobenzyl (trans-11g) substituents at N3 of the quinazolinone core showed the highest antiviral activity with an EC50 values in the range of 5.8\u201311.6 M. compounds possessing 3-fluorobenzyl (trans-11g), 4-fluorobenzyl (trans-11h) and 2,4-difluorobenzyl tra were performed in CDCl3 solution on the Varian Gemini 2000 BB at 81.0 MHz or on Bruker Avance III at 243.0 MHz. Melting points were determined on a Boetius apparatus (VEB Kombinat NAGEMA, Dresden, DDR\u2014currently Germany) the crude 6-bromo-2-vinylquinazolin-4(3H)-one was purified by crystallization from methanol. the crude 6-bromo-2-vinylquinazolin-4(3H)-one was stirred under reflux for 5 min. the solution was allowed to cool for 15 min and then acidified with acetic acid (1.6 mL) a solution of 6-bromo-2-vinyl-3H-quinazolin-4-one was added. the reaction mixture was stirred under reflux for 4 h. the solvent was removed and the residue was re-dissolved in methylene chloride. 1H-NMR (200 MHz, CDCl3): = 8.30\u20138.27 (m, 1H), 7.88\u20137.82 (m, 1H), 7.77\u20137.73 (m, 1H), 7.57\u20137.50 (m, 2H), 7.48\u20137.37 (m, 3H), 6.91 (dd, 3J = 17.2 Hz, 2J = 2.5 Hz, 1H, CH=CH2), 5.67 (s, 2H, N- 1H-NMR (151 MHz, CDCl3): = 8.33 (d, 4J = 2.2 Hz, 1H, HC5), 8.18\u20138.16 (m, 1H), 7.90 (dd, 3J = 8.9 Hz, 4J = 2.2 Hz, 1H, HC7), 7.81 (d, 3J = 8.9 Hz, 1H, HC8), 7.80\u20137.78 (m, 1H), 7.71\u20137. 1H-NMR (600 MHz, CDCl3): = 8.44 (brs, 1H), 8.32\u20138.30 (m, 1H), 8.26\u20138.24 (m, 1H), 7.91\u20137.88 (m, 1H), 7.80\u20137.78 (m, 1H), 7.64\u20137.61 (m, 1H), 6.73 (dd, 3J = 17.2 Hz, 2J = 1.4 Hz, 1H, CH= 1H-NMR (200 MHz, CDCl3): = 8.30\u20138.26 (m, 3H), 7.96\u20137.92 (m, 1H), 7.73\u20137.67 (m, 2H), 6.88 (dd, 3J = 17.2 Hz, 3J = 10.1 Hz, 2J = 2.1 Hz, 1H, CH=CH2), 5.77 (s, 2H, N-CH2). 1H-NMR (600 MHz, CDCl3): = 8.31 (d, 4J = 2.2 Hz, 1H, HC5), 7.89 (dd, 3J = 8.9 Hz, 4J = 2.2 Hz, 1H, HC7), 7.61\u20137.58 (m, 1H), 7.42\u20137.38 (m, 1H), 7.23\u20137.20 (m, 1H), 6.92 (dd, 3J = 17.2 Hz, 3 81, 130.70 (d, 3J(CCCF) = 4.0 Hz, C4\u2032), 130.39 (d, 3J(CCCF) = 7.9 Hz, C6\u2032), 129.47, 126.04, 124.44, 124.25 (d, 4J(CCCCF) = 3.4 Hz, C5\u2032), 123.24 (d, 2J(CCF) = 14.5 Hz, C3\u2032), 120.06, 3J = 17.1 Hz, 3J = 10.4 Hz, 1H, CH=CH2), 5.84 (dd, 3J = 10.4 Hz, 2J = 1.7 Hz, 1H, CH=CH2), 5.69 (s, 2H, N-CH2). 1H-NMR (200 MHz, CDCl3): = 8.26 (d, 4J = 2.1 Hz, 1H, HC5), 7.85 (dd, 3J = 8.9 Hz, 4J = 2.1 Hz, 1H, HC7), 7.75 (d, 3J = 8.9 Hz, 1H, HC8), 7.55\u20137.48 (m, 2H), 6.90 (dd, 3J = 17.2 Hz, 3J 1H-NMR (600 MHz, CDCl3): = 8.27 (d, 4J = 2.1 Hz, 1H, HC5), 7.88 (dd, 3J = 8.9 Hz, 4J = 2.1 Hz, 1H, HC7), 7.78 (d, 3J = 8.9 Hz, 1H, HC8), 7.59\u20137.55 (m, 1H), 6.96\u20136.89 (m, 2H), 6.72 (dd dd, 1J(CF) = 250.4 Hz, 3J(CCCF) = 12.0 Hz, C4\u2032), 160.15, 150.38, 150.38, 137.06, 136.80, 131.83 (dd, 3J(CCCF) = 9.8 Hz, 3J(CCCF) = 5.4 Hz, C6\u2032), 129.49, 125.95, 124.39, 120.12, 116.48, domethane (0.124 mL, 2.00 mmol) or iodoethane (0.088 mL, 1.10 mmol) was added and the reaction mixture was stirred at 60 \u00b0C for 5 h. the solvent was removed and the residue was re-dissolved in methylene chloride (10 mL) and extracted with water (3 10 mL) 13C-NMR (151 MHz, CDCl3): = 161.06 (C=O), 152.56, 146.20, 137.33, 129.34, 129.29, 128.92, 127.19, 121.95, 120.12, 30.95. a white amorphous solid, m.p. = 62\u201364 \u00b0C. t, 3J = 7.1 Hz, 2H, CH3CH2), 1.47 (t, 3J = 7.1 Hz, 3H, CH3CH2), 13C-NMR (151 MHz, CDCl3): = 161.06 (C=O), 160.37, 150.12, 136.90, 136.78, 129.34, 126.10, 124.19. 1H-NMR (600 MHz, CDCl3): = 10.63 (s, 1H, NH), 8.44 (d, 4J = 2.3 Hz, 1H, HC5\u2032), 7.84 (dd, 3J = 8.6 Hz, 4J = 2.3 Hz, 1H, HC7\u2032), 7.54 (d, 3J = 8.6 Hz, 1H, HC8\u2032), 5.02 (dd, 3J(H5\u2013H4) 1H-NMR (600 MHz, CDCl3): = 10.63 (s, 1H, NH), 8.44 (d, 4J = 2.3 Hz, 1H, HC5\u2032), 7.84 (dd, 3J = 8.6 Hz, 4J = 2.3 Hz, 1H, HC7\u2032), 7.54 (d, 3J = 8.6 Hz, 4J = 2.3 Hz, 1H, HC7\u2032), 7.54 (d, 3 8.6 Hz, 1H, HC8\u2032), 5.07 (dd, 3J(H5\u2013H4) = 9.2 Hz, 3J(H5\u2013H4) = 4.3 Hz, 1H, HC5), 4.23\u20134.12 (m, 4H, 2 CH2OP), 3.21 (ddd, 3J(H4\u2013P) = 19.8 Hz, 2J(H4\u2013H4) = 10.9 Hz, 3J(H4\u2013H4) 1H-NMR (600 MHz, CDCl3): = 8.33 (d, 4J = 2.3 Hz, 1H, HC5\u2032), 7.90 (dd, 3J = 8.9 Hz, 4J = 2.3 Hz, 1H, HC7\u2032), 7.55\u20137.53 (m, 2H), 7.45\u20137.42 (m, 2H), 7.40\u20137.37 (m, 1H), 7.40\u20137.37 (m, 1H), 7. 5.25 (dd, 3J(H5\u2013H4) = 6.8 Hz, 3J(H5\u2013H4) = 6.4 Hz, 1H, HC5), 4.33\u20134.19 (m, 4H, 2 CH2OP), 3.42\u20133.39 (m, 1H, HC3), 3.07\u20132.94 (m, 2H, HC4), 3.05 (s, 3H, CH3N), 1.42 (t, 3J = 7.0 Hz, 3 diethyl trans-5-[6-bromo-3-(2-nitrobenzyl)-4-oxo-3,4-dihydroquinazolin-2-yl]-2-methylisoxazolidin-3-ylphosphonate (trans-11c) found in yellowish oil. 2J(H4\u2013H4) = 16.6 Hz, 3J(H4\u2013H3) = 8.2 Hz, 3J(H4\u2013H5) = 8.0 Hz, 1H, HC4), 2.38 (dddd, 2J(H4\u2013H4) = 12.6 Hz, 3J(H4\u2013H3) = 10.2 Hz, 3J(H4\u2013H3) = 8.8 Hz, 3J (H4\u2013H5) = 6.1 Hz, 1H-NMR (243 MHz, CDCl3): = 8.44\u20138.42 (m, 1H), 8.32 (d, 4J = 2.0 Hz, 1H, HC5\u2032), 8.24\u20138.22 (m, 1H), 7.92 (dd, 3J = 8.9 Hz, 4J = 2.0 Hz, 1H, HC7\u2032), 7.90\u20137.88 (m, 1H), 7.84 (d, 3J = 8.9 Hz m, 2H, HC4, HC4), 3.07 (s, 3H, CH3N), 1.43 (t, 3J = 7.1 Hz, 3H, CH3CH2OP), 1.41 (t, 3J = 7.0 Hz, 3H, CH3CH2OP), 13C-NMR (151 MHz, CDCl3): = 21.52. 1H-NMR (600 MHz, CDCl3): = 8.35 (d, 4J = 2.0 Hz, 1H, HC5\u2032), 1H), 8.30\u20138.28 (m, 2H), 7.95 (dd, 3J = 8.9 Hz, 4J = 2.0 Hz, 1H, HC7\u2032), 7.72\u20137.71 (m, 2H), 5.76 (m, 2H), 5.24 (dd, 3J(H5\u2013H diethyl trans-5-[6-bromo-3-(2-fluorobenzyl)-4-oxo-3,4-dihydroquinazolin-2-yl]-2-methylisoxazolidin-3-ylphosphonate (trans-11f) was a mixture of trans-11f and cis-11f. 1H-NMR (600 MHz, CDCl3): = 8.31 (d, 4J = 2.1 Hz, 1H, HC5\u2032), 7.90 (d, 3J = 8.9 Hz, 4J = 2.1 Hz, 1H, HC7\u2032), 7.84 (d, 3J = 8.9 Hz, 1H, HC8\u2032), 7.58\u20137.55 (m, 1H), 7.40\u20137.36 (m, 1H), 7.21\u20137.1 163.31, 161.19 (d, 1J(CF) = 248.8 Hz, C2\u2032\u2032), 149.96, 137.25, 130.81 (d, 3J(CCCF) = 3.5 Hz, C4\u2032\u2032), 130.52 (d, 3J(CCCF) = 8.0 Hz, C6\u2032\u2032), 129.68, 125.94, 124.26 (d, 4J(CCCCF) = 3.4 Hz, C5\u2032\u2032 bromo-3-(3-fluorobenzyl)-4-oxo-3,4-dihydroquinazolin-2-yl]-2-methylisoxazolidin-3-ylphosphonate (trans-11g). bromo-3-(3-fluorobenzyl)-4-oxo-3,4-dihydroquinazolin-2-yl]-2-methylisoxazolidin-3-ylphospho 13C-NMR (151 MHz, CDCl3): = 165.84 (C=O), 163.22, 162.91, (d, 1J(CF) = 246.7 Hz, C3\u2032), 149.97, 138.18 (d, 3J(CCCF) = 7.6 Hz, C5\u2032), 137.31, 130.26 (d, J = 7.9 Hz, C1\u2032), 129.72, 125.84, 123.80 diethyl trans5-[6-bromo-3-(4-fluorobenzyl)-4-oxo-3,4-dihydroquinazolin-2-yl]-2-methylisoxazolidin-3-ylphosphonate (trans-11h) found in yellowish oil. 3J(H4\u2013H5) = 6.4 Hz, 1H, HC4), 1.42 (t, 3J = 7.0 Hz, 3H, CH3CH2OP), 1.40 (t, 3J = 7.1 Hz, 3H, CH3CH2OP), 31P-NMR (151 MHz, CDCl3): = 22.00. diethyl trans-5-[6-bromo-3-(2,4-difluorobenzyl)-4-oxo-3,4-dihydroquinazolin-2-yl]-2-methylisoxazolidin-3-ylphosphonate (trans-11i) data presented below were extracted from a 92:8 mixture of trans-11i and cis-11i. 3J(H4\u2013H4) = 12.8 Hz, 3J(H4\u2013H3) = 9.7 Hz, 3J(H4\u2013H5) = 6.5 Hz, 1H, HC4), 1.41 (t, 3J = 7.0 Hz, 3H, CH3CH2OP), 1.40 (t, 3J = 7.0 Hz, 3H, CH3CH2OP), 1.40 (t, 3J = 7.0 Hz, 3H, CH3CH2 d, 2J(COP) = 6.5 Hz, CH2OP), 62.43 (d, 2J(CCCF) = 6.3 Hz, CH2OP), 46.57 (d, 3J(CNCP) = 4.0 Hz, CH3N), 37.89 (C4), 16.56 (d, 3J(CCOP) = 5.7 Hz, CH3CH2OP), 16.50 (d, 3J(CCOP) = 5.6 Hz, CH3CH ddd, 3J(H5\u2013H4) = 7.6 Hz, 3J(H5\u2013H4) = 5.7 Hz, 1H, HC5), 4.29\u20134.23 (m, 4H, 2 CH2OP), 3.75 (s, 3H, CH3), 3.71 (dddd, 3J(H4\u2013P) = 12.6 Hz, 2J(H4\u2013H4) = 11.3 Hz, 3J(H4\u2013H3) = 9. 1H-NMR (600 MHz, CDCl3): = 8.32 (d, 4J = 2.2 Hz, 1H, HC5\u2032), 7.90 (dd, 3J = 8.8 Hz, 4J = 2.2.Hz, 1H, HC7\u2032), 7.82 (d, 3J = 8.8 Hz, 4J = 2.2.Hz, 1H, HC7\u2032), 5.23 (dd, 3J = 8.8 Hz, 1H, 8.0 Hz, 3J(H5\u2013H4) = 6.0 Hz, 1H, HC5), 4.68 (q, 3J = 7.2 Hz, 2H, CH3CH2), 4.33\u20134.21 (m, 4H, 2 CH2OP), 3.45\u20133.43 (m, 1H, HC3), 3.07 (s, 3H, CH3N), 3.06\u20133.01 (m, 1H, HC3), 2.97 (dddd, antiviral activity assays were based on inhibition of virus-induced cytopathicity or plaque formation in human embryonic lung (HEL) fibroblasts, human epithelial cervix carcinoma cells (HeLa), Crandell-Rees feline kidney cells (CRFK), or Madin Darby canine kidney cells. the cell cultures were inoculated with 100 CCID50 of virus (1 CCID50 being the virus dose to infect 50% of the cell cultures) or with 20 plaque forming units (PFU) the cell cultures were incubated in the presence of varying concentrations of the test compounds. general 1H-NMR spectra were taken in CDCl3 on the following spectrometers. the IC50 was defined as the compound concentration required to inhibit cell proliferation by 50%. IR spectra were measured on an Infinity MI-60 FT-IR spectrometer. 2-(3-chloropropionylamino)benzamide (2.03 g, 6.63 mmol) in 5% sodium hydroxide (16.4 mL) and ethanol (8.2 mL) was stirred under reflux for 5 min. the crude 6-bromo-2-vinyl-3H-quinazolin-4(3H)-one was purified by crystallization from methanol. d, 4J = 8.7 Hz, 4J = 2.4 Hz, 1H, HC7), 7.90 (dd, 3J = 8.7 Hz, 1H, HC8), 6.63 (dd, 3J = 17.5 Hz, 2J = 3.7 Hz, 1H, CH=CH2), 6.53 (dd, 3J = 17.5 Hz, 3J = 8.1 Hz, 1H, CH=CH2), 5.86 (dd, an organic phase was dried (MgSO4), concentrated, and the crude product was purified on a silica gel column with a methylene chloride:hexane (7:3, v/v) mixture followed by crystallization (chloroform-petroleum ether or ethyl acetate) anal. Calcd. for C17H13BrN2O: C, 59.84; H, 3.84; N, 8.29. found: 6-Bromo-3-(2-nitrobenzyl)-2-vinylquinazolin-4(3H)-one (13c) 13C-NMR (151 MHz, CDCl3): = 164.62 (C=O), 160.12, 150.32, 147.84, 137.31, 136.31, 133.78, 132.33, 129.51, 129.05, 128.87, 125.76, 125.07, 120.38, 116.31, 65.14 (N-CH2). Hz, 2J = 1.4 Hz, 1H, CH=CH2), 5.84 (dd, 3J = 10.4 Hz, 2J = 1.4 Hz, 1H, CH=CH2), 5.78 (s, 2H, N-CH2). 13C-NMR (151 MHz, CDCl3): = 164.69 (C=O), 160.05, 150.49, 148.51, 138.14, 137.28, 136.68, 134 1H-NMR (600 MHz, CDCl3): = 8.31 (d, 4J = 2.2 Hz, 1H, HC5), 7.89 (dd, 3J = 8.9 Hz, 4J = 2.2 Hz, 1H, HC7), 7.68 (d, 3J = 8.9 Hz, 4J = 2.2 Hz, 1H, HC7), 7.42\u20137.38 (m, 1H), 7.42\u20137.38 (m, 1 dd, 3J = 17.2 Hz, 3J = 10.4 Hz, 1H, CH=CH2), 5.84 (dd, 3J = 10.4 Hz, 2J = 1.7 Hz, 1H, CH=CH2), 5.78 (s, 2H, N-CH2), 5.78 (s, 2H, N-CH2). 1H-NMR (600 MHz, CDCl3): = 8.32 (d, 4J = 2.2 Hz, 1H, HC5), 7.89 (dd, 3J = 8.9 Hz, 4J = 2.2 Hz, 1H, HC7), 7.43\u20137.39 (m, 1H), 7.34\u20137.32 (m, 1H), 7.28\u20137.26 (m, 1H), 7.11\u20137.08 (m, 1H), 6.92 (d d, 4J(CCCCF) = 3.1 Hz, C6\u2032, 120.18, 116.54, 115.33 (d, 2J(CCF) = 21.0 Hz, C4\u2032), 115.14 (d, 2J(CCF) = 22.0 Hz, C2\u2032), 67.77 (d, 4JCCCCF = 1.5 Hz, N-CH2), 5.82 (dd, 3J = 17.2 Hz, 3J = 13C-NMR (151 MHz, CDCl3): = 165.04 (C=O), 162.82 (d, 1J(CF) = 247.1 Hz, C4\u2032), 160.20, 150.40, 150.40, 150.40, 150.40, 137.04, 136.88, 131.84 (d, 4J(CCCCF) = 3.1 Hz, C1\u2032), 130.39 (d, 3J(CCCF) = 8.9 Hz, 4J = 2.1 Hz, 1H, HC7), 7.78 (d, 3J = 8.9 Hz, 1H, HC8), 7.59\u20137.55 (m, 1H), 6.96\u20136.89 (m, 2H), 6.89 (dd, 3J = 17.2 Hz, 3J = 10.0 Hz, 1H, CH=CH2), 6.72 (dd, 3J = 17.2 Hz, 2J = 2.4 the solution of 6-bromo-2-vinyl-3H-quinazolin-4-one was added. the solvent was removed and the residue was re-dissolved in methylene chloride (10 mL) and extracted with water (3 10 mL) 1H-NMR (200 MHz, CDCl3): = 8.21 (d, 4J = 2.1 Hz, 1H, HC5), 7.79 (dd, 3J = 8.9 Hz, 4J = 2.1 Hz, 1H, HC7), 7.67 (dd, 3J = 8.9 Hz, 1H, HC8), 6.83 (dd, 3J = 17.2 Hz, 3J = 9.9 Hz, 1H, CH= 1H-NMR (200 MHz, CDCl3): = 8.22 (d, 4J = 2.2 Hz, 1H, HC5), 7.79 (dd, 3J = 8.9 Hz, 4J = 2.2 Hz, 1H, HC7), 7.68 (dd, 3J = 8.9 Hz, 1H, HC8), 6.82 (dd, 3J = 17.2 Hz, 3J = 10.0 Hz, 1H, CH= crude products were subjected to chromatography on silica gel columns with chloroform:methanol (100:1, 50:1, 20:1, v/v) mixtures. diethyl trans-[5-(6-bromo-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylisoxazolidin-3-yl]phosphonate (trans-11a) 8.6 Hz, 3J(H4\u2013H3) = 8.3 Hz, 1H, HC4), 2.94 (ddd, 3J(H4\u2013H3) = 12.9 Hz, 3J(H4\u2013H3) = 10.0 Hz, 3J(H4\u2013H5) = 6.2 Hz, 1H, HC4), 1.40 (t, 3J = 7.1 Hz, 3H, CH3CH2OP), 1.38 (t, 3J = IR (film, cm1) max: 3090, 2959, 2925, 2865, 1661, 1626, 1601, 1461, 1336, 1234, 1054, 969, 834, 575. mo-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylisoxazolidin-3-yl]phosphonate (cis-11a) 3J(H4\u2013H3) = 9.6 Hz, 3J(H4\u2013H5) = 9.2 Hz, 1H, HC4), 1.32 (t, 3J = 7.0 Hz, 3H, 3H, CH3CH2OP), 1.27 (t, 3J = 7.1 Hz, 3H, CH3CH2OP), 31P-NMR (243 MHz, CDCl3): = 20.92. 1H-NMR (600 MHz, CDCl3): = 8.33 (d, 4J = 2.3 Hz, 1H, HC5\u2032), 7.90 (dd, 3J = 8.9 Hz, 4J = 2.3 Hz, 1H, HC7\u2032), 7.55\u20137.53 (m, 2H), 7.45\u20137.42 (m, 2H), 7.40\u20137.37 (m, 1H), 5.66 (dd, 3J = 6.8 1H-NMR (600 MHz, CDCl3): = 8.36 (d, 4J = 2.0 Hz, 1H, HC5\u2032), 8.20\u20138.18 (m, 1H), 7.95 (dd, 3J = 8.9 Hz, 4J = 2.3 Hz, HC7\u2032), 7.87 (dd, 3J = 8.9 Hz, 4J = 2.3 Hz, 1H, HC7\u2032). 4J = 8.9 Hz, 1H, HC8\u2032), 7.78\u20137.76 (m, 1H), 7.72\u20137.69 (m, 1H), 7.57\u20137.55 (m, 1H), 6.10 (AB, JAB = 14.6 Hz, 1H, N-CH2b), 6.07 (dd, 3J(H5\u2013H4) = 8.0 Hz, 3J(H5\u2013H4) = 6.1 Hz, 1H, HC4) d, 3J(CCCP) = 7.8 Hz, C5), 65.64 (N-CH2), 64.30 (d, 1J(CP) = 168.5 Hz, C3), 63.21 (d, 2J(COP) = 6.3 Hz, CH2OP), 46.61 (d, 3J(CNCP) = 4.2 Hz, CH3N) dd, 3J = 8.9 Hz, 4J = 2.0 Hz, 1H, HC7\u2032. 7.90\u20137.88 (m, 1H), 7.84 (d, 3J = 8.9 Hz, 1H, HC8\u2032), 7.63\u20137.60 (m, 1H), 5.77 (s, 2H, N-CH2), 5.29 (dd, 3J(H5\u2013H4) = 8.0 Hz, 3J(H5\u2013H 1H-NMR (600 MHz, CDCl3): = 8.35 (d, 4J = 2.0 Hz, 1H, HC5\u2032), 1H), 8.30\u20138.28 (m, 2H), 7.95 (dd, 3J = 8.9 Hz, 4J = 2.0 Hz, 1H, HC7\u2032), 7.72\u20137.71 (m, 2H), 5.76 (dd, 3J = 8.9 Hz, 1H, HC8\u2032 m, 1H, HC3), 3.07\u20132.98 (m, 1H, HC4), 3.03 (s, 3H, CH3-N), 2.94 (dddd, 3J(H4\u2013P) = 12.4 Hz, 2J(H4\u2013H4) = 12.4 Hz, 3J(H4\u2013H3) = 9.2 Hz, 3J(H4\u2013H5) = 6.0 Hz, 1H, HC4), 1.41 (t diethyl trans-5-[6-bromo-3-(2-fluorobenzyl)-4-oxo-3,4-dihydroquinazolin-2-yl]-2-methylisoxazolidin-3-ylphosphonate (trans-11f) data presented below were extracted from a 88:12 mixture of trans-11f and cis-11f. 3.42\u20133.39 (m, 1H, C3), 3.05 (s, 3H, CH3-N), 3.03\u20132.96 (m, 1H, HC4), 2.96 (dddd, 3J(H4\u2013P) = 12.5 Hz, 2J(H4\u2013H4) = 12.5 Hz, 3J(H4\u2013H3) = 8.9 Hz, 3J(H4\u2013H5) = 6.2 Hz, 1H, HC4), 1H-NMR (200 MHz, CDCl3): = 8.35\u20138.33 (m, 1H), 7.91\u20137.89 (m, 1H), 7.41\u20137.37 (m, 1H), 7.30\u20137.28 (m, 1H), 7.26\u20137.24 (m, 1H), 7.08\u20137.05 (m, 1H), 5.24 (dd, 3J(H5), 5.24 (dd, 3J(H5), 5.24 (dd \u2013H4) = 7.9 Hz, 3J(H5\u2013H4) = 6.5 Hz, 1H, HC5), 4.33\u20134.17 (m, 4H, 2 CH2OP), 3.05\u20132.99 (m, 1H, HC4), 2.95 (dddd, 3J(H4\u2013P) = 12.7 Hz, 2J(H4\u2013H4) = 12.7 Hz, 3J(H4\u2013H3) = 9.7 Hz, 3 d, 1J(CP) = 168.3 Hz, C3), 63.24 (d, 2J(COP) = 6.4 Hz, CH2OP), 46.57 (d, 3J(CNCP) = 3.7 Hz, CH3N), 37.84 (s, C4), 16.55 (d, 3J(CCOP) = 5.6 Hz, CH3CH2OP), 16.49 (d, 3J(CCOP) = 5.9 Hz, CH HC8\u2032), 7.55\u20137.53 (m, 2H), 7.14\u20137.11 (m, 2H), 5.63 (s, 1H, N-CH2), 5.26 (dd, 3J(H5\u2013H4) = 6.4 Hz, 3J(H5\u2013H4) = 6.4 Hz, 1H, HC5), 4.34\u20134.22 (m, 4H, 2 CH2OP), 3.41\u20133.39 (m, 1H, C3), 3.07 68.40 (N-CH2), 64.43 (d, 1J(CP) = 168.3 Hz, C3), 63.26 (d, 2J(COP) = 6.5 Hz, CH2OP), 46.59 (CH3N), 37.87 (C4), 16.56 (d, 3J(CCOP) = 5.8 Hz, CH3CH2OP), 16.46 (d, 3J(CCOP) = 5.3 Hz, CH3CH2 7.85 (d, 3J = 8.8 Hz, 1H, HC8\u2032), 7.59\u20137.55 (m, 1H), 6.95\u20136.89 (m, 2H), 5.68 (AB, JAB = 13.3 Hz, 1H, N-CH2a), 5.25 (dd, 3J(H5\u2013H4) = 7.7 Hz, 3J(H5\u2013H4) = 6.5 Hz, 1H, HC5), 4.33\u20134.18 ( Hz, 3J(CCCF) = 4.9 Hz, C6\u2032\u2032, 129.71, 125.87, 120.81, 118.98 (dd, 2J(CCF) = 14.4 Hz, 4J(CCCCF) = 3.4 Hz, C1\u2032\u2032), 116.58, 111.51 (dd, 2J(CCF) = 21.1 Hz, 4J(CCCCF) = 3.5 Hz, C5\u2032\u2032), 5-[6-bromo-3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]-2-methylisoxazolidin-3-ylphosphonate (trans-11j) IR (film, cm1) max: 3521, 3477, 2976, 2912, 2855, 1687, 1606, 1470, 1308, 1265, 1050, 1023, 1023, 849, 574. 15 Hz, 2J(H4\u2013H4) = 11.3 Hz, 3J(H4\u2013H3) = 7.6 Hz, 1H, HC4), 1.41 (t, 3J = 7.0 Hz, 3H, CH3CH2OP), 1.40 (t, 3J = 7.1 Hz, 3H, CH3CH2OP), 13C-NMR (151 MHz, CDCl3): = 161.31 (C=O), 152.70, 1H-NMR (600 MHz, CDCl3): = 8.32 (d, 4J = 2.2 Hz, 1H, HC5\u2032), 7.90 (dd, 3J = 8.8 Hz, 4J = 2.2.Hz, 1H, HC7\u2032), 7.82 (d, 3J = 8.8 Hz, 1H, HC8\u2032), 5.23 (dd, 3J = 8.0 Hz, 3J(H5\u2013H4) = 6.0 13C-NMR (151 MHz, CDCl3): =166.33 (C=O), 163.63, 149.78, 137.01, 129.63, 126.03, 120.47, 116.78, 80.22 (d, 3J(CCCP) = 7.9 Hz, C5), 64.38 (d, 1J(CP) = 168.0 Hz, C3), 63.28 (d, 2J(COP) = 6.4 sicular stomatitis virus, para-influenza-3 virus, reovirus-1, Sindbis virus, reovirus-1, Sindbis virus, respiratory syncytial virus (RSV), feline coronovirus (FIPV) and influenza A virus subtypes H1N1 (A/PR/8), H3N2 (A/HK/7/87) and influenza B virus (B/HK/5/72) the cytostatic concentration was calculated as the CC50, or the compound concentration required to reduce cell proliferation by 50%. the IC50 was defined as the compound concentration required to inhibit cell proliferation by 50%. almost all compounds were active against VZV and among them trans-11b, trans-11d, trans-11g, and trans-11h were the most potent (EC50 = 5.8\u201311.6 ) and, at the same time, exhibited lower cytotoxicity toward uninfected cell lines."}{"summary": "human cytomegalovirus (HCMV) and varicella zoster virus (VZV) belong to the family of herpesviruses which cause infections usually acquired in childhood [1,2,3] despite the wide range of available drugs, effective treatment of viral infections is still limited. new compounds with potential biological activity are being sought all the time. o-2-phenyl-4H-quinazolin-3-yl)-benzoic acid 1 showed antiviral activity against both herpes simplex viruses 1 and 2 (HSV-1 and HSV-2) and vaccinia virus (EC50 = 12 g/mL) compound 2 showed antiviral activity against vaccinia virus in vivo. compound (aS)-9 exhibited higher potency for PI4KIII than its atropisomer aR (pIC50 of 8.3 vs. 6.9) and an improved selectivity range against the other lipid kinases. a series of quinazolinones substituted at C3 with a (diethoxyphosphoryl)isoxazolidine moiety 10 was synthesized. isatoic acid anhydride was first reacted with bromine and then transformed into 5-bromoanthranilic acid amide 14 according to the procedure in the literature [27,28] cyclization and dehydrohalogenation led to the formation of 6-bromo-2-vinyl-3H-quinazolin-4-one 13a, which was then used as a key intermediate in the preparation of N3-substituted derivatives 13b\u201313k via al in all cases good trans/cis diastereoselectivities were observed (in the range of 76\u201388%) and trans-isomers predominated. isoxazolidine cycloadducts were separated chromatographically on silica gel. cis-11c (62) b d 3-NO2-C6H4-CH2 92:8 trans-11d (14) a + trans-11d and cis-11d (80) b e 2-F-C6H4-CH2 90:10 trans-11e (18) a + trans-11e and cis-11e (72) b f 2-F-C6H4-CH2 90:10 trans-11f and cis-11f (96) b stituted 2-vinyl-3H-quinazolin-4-ones, trans and cis configurations of major trans-11a\u2013k and minor cis-11a\u2013k isomers were assigned taking advantage of previous observations. antiviral and Cytostatic evaluation 2.2.1. acyclovir, brivudin, zalcitabine, zanamivir, alovudine, amantadine, rimantadine, ribavirin, dextran sulfate (molecular weight 10000, DS-10000), mycophenolic acid, Hippeastrum hybrid agglutinin (HHA) and Urtica dioica agglutinin (UDA) were used as reference compounds incorporation of the bromine atom at C6 in the quinazolinone skeleton resulted in a significant increase in potency of isoxazolidine-conjugates 11b\u201311i against VZV. compared with previously described analogous conjugates 10b\u201310i having an unsubstituted quinazoline skeleton [25]. trans-11i/cis-11i (92:8) 2,4-diF-C6H3-CH2 8.7 3.2 10.5 0.3 >20 15.6 3.2 trans-11j CH3 >4 >4 20 n.d. acyclovir 1.55 1.0 39.2 3.6 >440 >350 Brivudin 0.023 0.008 31.9 16.1 >300 >300 a Effective concentration required to reduce virus plaque formation by 50%, n.d.\u2014not determined trans-11c 2-NO2-C6H4-CH2 >20 15.29 100 n.d. trans-11d 3-NO2-C6H4-CH2 10.4 0.8 11.6 2.5 100 37.0 4.3 trans-11e 4-NO2-C6H4-CH2 >20 >20 100 n.d. trans-11f/cis-11f (95:5) 2-F-C6H4-CH2 8.94 8.94 20 n.d. trans-11g 3-F-C6H4 almost all compounds 11a\u201311k showed inhibitory activity against the proliferation of tumour cell lines. they appeared to be the most cytostatic toward the human T-lymphocyte (CEM) cell line with an inhibitory effect in the 9.6\u201333 M range. 2-C6H4-CH2 26 1 33 25 24 9 30 0 trans-11e 4-NO2-C6H4-CH2 18 76 17 12 24 9 26 6 trans-11f/cis-11f (95:5) 2-F-C6H4-CH2 17 2 13 1 25 7 30 0 trans-11g 3-F-C6H4-CH2 16 2 10 0 25 7 30 0 trans-11h 4-F-C6H4-CH2 16 0 9.6 2.2 idine phosphonates having 3-nitrobenzyl (trans-11d) and 3-fluorobenzyl (trans-11g) substituents at N3 of the quinazolinone core showed the highest antiviral activity with an EC50 values in the range of 5.8\u201311.6 M. isoxazolidines having 2-nitrobenzyl (trans-11c) and 2,4-difluorobenzyl (trans-11i/cis-11i (92:8) uted derivatives 13b\u201313k via alkylation with the respective benzyl bromides, as well as with methyl or ethyl iodide [29] (Scheme 2). Scheme 2. Synthesis of 3-substituted 6-bromo-2-vinylquinazolinones 13a\u201313k. trans-11d (R = 3-NO2-C6H4-CH2), trans-11g (R = 3-F-C6H4-CH2), trans-11h (R = 4-F-C6H4-CH2), trans-11j (R = CH3), and trans-11k (R = CH3), as well as for a minor isomer cis-11a (R = H). cis-11g (72) b h 4-F-C6H4-CH2 92:8 trans-11h (12) a + trans-11h and cis-11h (82) b j CH3 94:6 trans-11j (32) a + trans-11j and cis-11j (65) b k CH3CH2 88:12 trans-11k (14) a + trans-11k and cis-11k (80) b yield of pure mixture of azolidines trans-11f/cis-11f (95:5) and trans-11i/cis-11i (92:8) were tested for inhibitory activity against a wide variety of DNA and RNA viruses. the following cell-based assays were used: human embryonic lung (HEL) cells (herpes simplex virus-1 (KOS strain), herpes simplex virus-2 (G strain), thymidine kinase deficient (acyclovir resistant) her tica dioica agglutinin (UDA) were used as reference compounds. the antiviral activity was expressed as the EC50: the compound concentration required to reduce virus plaque formation (VZV) by 50% or to reduce virus-induced cytopathogenicity by 50%. TK+ VZV Strain (07-1) Cell Morphology MCC b Cell Growth CC50 c cis-11a H >100 >100 >100 >100 n.d. trans-11b C6H5-CH2 13.5 7.1 13.6 9.1 100 42.3 0.3 trans-11c 2-NO2-C6H4-CH2 10.3 1.1 5.4 1.0 100 9.4 0.4 trans-11d 3-NO2-C6H4-CH2 8.3 1.4 5. c Cytotoxic concentrations required to reduce cell growth by 50%, n.d.\u2014not determined. the synthesized isoxazolidine phosphonates also showed marked activity against human cytomegalovirus (HCMV) -C6H4-CH2 10.5 2.2 8.94 0 100 33.0 3.5 trans-11h 4-F-C6H4-CH2 12.5 3.9 11.2 3.1 100 39.4 5.2 trans-11i/cis-11i (92:8) 2,4-diF-C6H3-CH2 9.4 0.46 9.7 1.1 >20 15.6 3.2 trans-11j CH3 >20 >100 20 n.d. trans-11k CH3CH2 > trans-11f/cis-11f (95:5) (IC50 = 13 1 M), trans-11g (IC50 = 10 0 M), trans-11h (IC50 = 9.6 2.2 M), and trans-11i/cis-11i (92:8) exhibited activity toward the CEM line higher than of 5-fluorouracil (IC50 = 18 5 M) 0 9.6 2.2 25 7 29 1 trans-11i/cis-11i (92:8) 2,4-diF-C6H3-CH2 16 1 9.8 4.8 22 6 30 0 trans-11j CH3 138 19 128 21 175 105 >250 trans-11k/cis-11k (97:3). a 50% Inhibitory concentration or compound concentration required to inhibit tumor cell proliferation by 50%, n.d.\u2014not determined. isoxazolidines have 2-nitrobenzyl (trans-11c) and 2,4-difluorobenzyl (trans-11i/cis-11i (92:8)) substituents at same position of a quinazolinone moiety appeared to be the most active toward the human cervix carcinoma cell line. their inhibitory concentration was much lower than that of the reference drugs. reovirus-1, Sindbis virus, Coxsackie virus B4, Punta Toro virus, yellow fever virus. acyclovir, brivudin, zalcitabine, zanamivir, alovudine, amantadine, rimantadine, ribavirin, dextran sulfate (molecular weight 10000, DS-10000), mycophenolic acid, hippeastrum hybrid agg compounds trans-11b, trans-11d, trans-11g, and trans-11h exhibited the lowest cytotoxicity (CC50 = 33\u201342 ). incorporation of the bromine atom at C6 in the quinazolinone skeleton resulted in a significant increase in potency of isoxazolidine-conjugates 11b\u201311i against VZV. acyclovir 1.55 1.0 39.2 3.6 >440 >350 Brivudin 0.023 0.008 31.9 16.1 >300 >300 a Effective concentration required to reduce virus plaque formation by 50%. activities of the tested compounds against both AD-169 and Davis strains were comparable (EC50 = 8.9\u201312.5 ) to that of Ganciclovir (EC50 = 16.9 and 7.7 ) used as a reference drug. c cis-11a H >100 >100 100 n.d. trans-11b C6H5-CH2 20 20 20 n.d. trans-11c 2-NO2-C6H4-CH2 10.4 0.8 11.6 2.5 100 37.0 4.3 trans-11e 4-NO2-C6H4-CH2 >20 >20 100 n.d. trans-11f/cis-11f (95:5) 2-F-C6H4-CH2 8.94 8.94 20 n cytostatic activity (IC50) causing a 50% decrease in cell proliferation was determined against murine leukemia L1210, human lymphocyte CEM, human cervix carcinoma HeLa, and immortalized human dermal microvacsular endothelial cells (HMEC-1). Almost all compounds 11a\u201311k showed inhibitory activity against the proliferation of tumour cell lines. -11b C6H5-CH2 20 2 16 3 26 7 30 0 trans-11c 2-NO2-C6H4-CH2 19 3 14 4 22 11 30 0 trans-11d 3-NO2-C6H4-CH2 26 1 33 25 24 9 30 0 trans-11e 4-NO2-C6H4-CH2 26 76 17 12 24 9 26 6 trans-11f/cis-11f (95:5) 2-F-C6H4-CH2 17 2 13 1 25 7 isoxazolidine phosphonates having 3-nitrobenzyl (trans-11d) and 3-fluorobenzyl (trans-11g) substituents at N3 of the quinazolinone core showed the highest antiviral activity with an EC50 values in the range of 5.8\u201311.6 M. compounds possessing 3-fluorobenzyl (trans-11g), 4-fluorobenzyl (trans-11h) and 2,4-difluorobenzyl tra were performed in CDCl3 solution on the Varian Gemini 2000 BB at 81.0 MHz or on Bruker Avance III at 243.0 MHz. Melting points were determined on a Boetius apparatus (VEB Kombinat NAGEMA, Dresden, DDR\u2014currently Germany) the crude 6-bromo-2-vinylquinazolin-4(3H)-one was purified by crystallization from methanol. the crude 6-bromo-2-vinylquinazolin-4(3H)-one was stirred under reflux for 5 min. the solution was allowed to cool for 15 min and then acidified with acetic acid (1.6 mL) a solution of 6-bromo-2-vinyl-3H-quinazolin-4-one was added. the reaction mixture was stirred under reflux for 4 h. the solvent was removed and the residue was re-dissolved in methylene chloride. 1H-NMR (200 MHz, CDCl3): = 8.30\u20138.27 (m, 1H), 7.88\u20137.82 (m, 1H), 7.77\u20137.73 (m, 1H), 7.57\u20137.50 (m, 2H), 7.48\u20137.37 (m, 3H), 6.91 (dd, 3J = 17.2 Hz, 2J = 2.5 Hz, 1H, CH=CH2), 5.67 (s, 2H, N- 1H-NMR (151 MHz, CDCl3): = 8.33 (d, 4J = 2.2 Hz, 1H, HC5), 8.18\u20138.16 (m, 1H), 7.90 (dd, 3J = 8.9 Hz, 4J = 2.2 Hz, 1H, HC7), 7.81 (d, 3J = 8.9 Hz, 1H, HC8), 7.80\u20137.78 (m, 1H), 7.71\u20137. 1H-NMR (600 MHz, CDCl3): = 8.44 (brs, 1H), 8.32\u20138.30 (m, 1H), 8.26\u20138.24 (m, 1H), 7.91\u20137.88 (m, 1H), 7.80\u20137.78 (m, 1H), 7.64\u20137.61 (m, 1H), 6.73 (dd, 3J = 17.2 Hz, 2J = 1.4 Hz, 1H, CH= 1H-NMR (200 MHz, CDCl3): = 8.30\u20138.26 (m, 3H), 7.96\u20137.92 (m, 1H), 7.73\u20137.67 (m, 2H), 6.88 (dd, 3J = 17.2 Hz, 3J = 10.1 Hz, 2J = 2.1 Hz, 1H, CH=CH2), 5.77 (s, 2H, N-CH2). 1H-NMR (600 MHz, CDCl3): = 8.31 (d, 4J = 2.2 Hz, 1H, HC5), 7.89 (dd, 3J = 8.9 Hz, 4J = 2.2 Hz, 1H, HC7), 7.61\u20137.58 (m, 1H), 7.42\u20137.38 (m, 1H), 7.23\u20137.20 (m, 1H), 6.92 (dd, 3J = 17.2 Hz, 3 81, 130.70 (d, 3J(CCCF) = 4.0 Hz, C4\u2032), 130.39 (d, 3J(CCCF) = 7.9 Hz, C6\u2032), 129.47, 126.04, 124.44, 124.25 (d, 4J(CCCCF) = 3.4 Hz, C5\u2032), 123.24 (d, 2J(CCF) = 14.5 Hz, C3\u2032), 120.06, 3J = 17.1 Hz, 3J = 10.4 Hz, 1H, CH=CH2), 5.84 (dd, 3J = 10.4 Hz, 2J = 1.7 Hz, 1H, CH=CH2), 5.69 (s, 2H, N-CH2). 1H-NMR (200 MHz, CDCl3): = 8.26 (d, 4J = 2.1 Hz, 1H, HC5), 7.85 (dd, 3J = 8.9 Hz, 4J = 2.1 Hz, 1H, HC7), 7.75 (d, 3J = 8.9 Hz, 1H, HC8), 7.55\u20137.48 (m, 2H), 6.90 (dd, 3J = 17.2 Hz, 3J 1H-NMR (600 MHz, CDCl3): = 8.27 (d, 4J = 2.1 Hz, 1H, HC5), 7.88 (dd, 3J = 8.9 Hz, 4J = 2.1 Hz, 1H, HC7), 7.78 (d, 3J = 8.9 Hz, 1H, HC8), 7.59\u20137.55 (m, 1H), 6.96\u20136.89 (m, 2H), 6.72 (dd dd, 1J(CF) = 250.4 Hz, 3J(CCCF) = 12.0 Hz, C4\u2032), 160.15, 150.38, 150.38, 137.06, 136.80, 131.83 (dd, 3J(CCCF) = 9.8 Hz, 3J(CCCF) = 5.4 Hz, C6\u2032), 129.49, 125.95, 124.39, 120.12, 116.48, domethane (0.124 mL, 2.00 mmol) or iodoethane (0.088 mL, 1.10 mmol) was added and the reaction mixture was stirred at 60 \u00b0C for 5 h. the solvent was removed and the residue was re-dissolved in methylene chloride (10 mL) and extracted with water (3 10 mL) 13C-NMR (151 MHz, CDCl3): = 161.06 (C=O), 152.56, 146.20, 137.33, 129.34, 129.29, 128.92, 127.19, 121.95, 120.12, 30.95. a white amorphous solid, m.p. = 62\u201364 \u00b0C. t, 3J = 7.1 Hz, 2H, CH3CH2), 1.47 (t, 3J = 7.1 Hz, 3H, CH3CH2), 13C-NMR (151 MHz, CDCl3): = 161.06 (C=O), 160.37, 150.12, 136.90, 136.78, 129.34, 126.10, 124.19. 1H-NMR (600 MHz, CDCl3): = 10.63 (s, 1H, NH), 8.44 (d, 4J = 2.3 Hz, 1H, HC5\u2032), 7.84 (dd, 3J = 8.6 Hz, 4J = 2.3 Hz, 1H, HC7\u2032), 7.54 (d, 3J = 8.6 Hz, 1H, HC8\u2032), 5.02 (dd, 3J(H5\u2013H4) 1H-NMR (600 MHz, CDCl3): = 10.63 (s, 1H, NH), 8.44 (d, 4J = 2.3 Hz, 1H, HC5\u2032), 7.84 (dd, 3J = 8.6 Hz, 4J = 2.3 Hz, 1H, HC7\u2032), 7.54 (d, 3J = 8.6 Hz, 4J = 2.3 Hz, 1H, HC7\u2032), 7.54 (d, 3 8.6 Hz, 1H, HC8\u2032), 5.07 (dd, 3J(H5\u2013H4) = 9.2 Hz, 3J(H5\u2013H4) = 4.3 Hz, 1H, HC5), 4.23\u20134.12 (m, 4H, 2 CH2OP), 3.21 (ddd, 3J(H4\u2013P) = 19.8 Hz, 2J(H4\u2013H4) = 10.9 Hz, 3J(H4\u2013H4) 1H-NMR (600 MHz, CDCl3): = 8.33 (d, 4J = 2.3 Hz, 1H, HC5\u2032), 7.90 (dd, 3J = 8.9 Hz, 4J = 2.3 Hz, 1H, HC7\u2032), 7.55\u20137.53 (m, 2H), 7.45\u20137.42 (m, 2H), 7.40\u20137.37 (m, 1H), 7.40\u20137.37 (m, 1H), 7. 5.25 (dd, 3J(H5\u2013H4) = 6.8 Hz, 3J(H5\u2013H4) = 6.4 Hz, 1H, HC5), 4.33\u20134.19 (m, 4H, 2 CH2OP), 3.42\u20133.39 (m, 1H, HC3), 3.07\u20132.94 (m, 2H, HC4), 3.05 (s, 3H, CH3N), 1.42 (t, 3J = 7.0 Hz, 3 diethyl trans-5-[6-bromo-3-(2-nitrobenzyl)-4-oxo-3,4-dihydroquinazolin-2-yl]-2-methylisoxazolidin-3-ylphosphonate (trans-11c) found in yellowish oil. 2J(H4\u2013H4) = 16.6 Hz, 3J(H4\u2013H3) = 8.2 Hz, 3J(H4\u2013H5) = 8.0 Hz, 1H, HC4), 2.38 (dddd, 2J(H4\u2013H4) = 12.6 Hz, 3J(H4\u2013H3) = 10.2 Hz, 3J(H4\u2013H3) = 8.8 Hz, 3J (H4\u2013H5) = 6.1 Hz, 1H-NMR (243 MHz, CDCl3): = 8.44\u20138.42 (m, 1H), 8.32 (d, 4J = 2.0 Hz, 1H, HC5\u2032), 8.24\u20138.22 (m, 1H), 7.92 (dd, 3J = 8.9 Hz, 4J = 2.0 Hz, 1H, HC7\u2032), 7.90\u20137.88 (m, 1H), 7.84 (d, 3J = 8.9 Hz m, 2H, HC4, HC4), 3.07 (s, 3H, CH3N), 1.43 (t, 3J = 7.1 Hz, 3H, CH3CH2OP), 1.41 (t, 3J = 7.0 Hz, 3H, CH3CH2OP), 13C-NMR (151 MHz, CDCl3): = 21.52. 1H-NMR (600 MHz, CDCl3): = 8.35 (d, 4J = 2.0 Hz, 1H, HC5\u2032), 1H), 8.30\u20138.28 (m, 2H), 7.95 (dd, 3J = 8.9 Hz, 4J = 2.0 Hz, 1H, HC7\u2032), 7.72\u20137.71 (m, 2H), 5.76 (m, 2H), 5.24 (dd, 3J(H5\u2013H diethyl trans-5-[6-bromo-3-(2-fluorobenzyl)-4-oxo-3,4-dihydroquinazolin-2-yl]-2-methylisoxazolidin-3-ylphosphonate (trans-11f) was a mixture of trans-11f and cis-11f. 1H-NMR (600 MHz, CDCl3): = 8.31 (d, 4J = 2.1 Hz, 1H, HC5\u2032), 7.90 (d, 3J = 8.9 Hz, 4J = 2.1 Hz, 1H, HC7\u2032), 7.84 (d, 3J = 8.9 Hz, 1H, HC8\u2032), 7.58\u20137.55 (m, 1H), 7.40\u20137.36 (m, 1H), 7.21\u20137.1 163.31, 161.19 (d, 1J(CF) = 248.8 Hz, C2\u2032\u2032), 149.96, 137.25, 130.81 (d, 3J(CCCF) = 3.5 Hz, C4\u2032\u2032), 130.52 (d, 3J(CCCF) = 8.0 Hz, C6\u2032\u2032), 129.68, 125.94, 124.26 (d, 4J(CCCCF) = 3.4 Hz, C5\u2032\u2032 bromo-3-(3-fluorobenzyl)-4-oxo-3,4-dihydroquinazolin-2-yl]-2-methylisoxazolidin-3-ylphosphonate (trans-11g). bromo-3-(3-fluorobenzyl)-4-oxo-3,4-dihydroquinazolin-2-yl]-2-methylisoxazolidin-3-ylphospho 13C-NMR (151 MHz, CDCl3): = 165.84 (C=O), 163.22, 162.91, (d, 1J(CF) = 246.7 Hz, C3\u2032), 149.97, 138.18 (d, 3J(CCCF) = 7.6 Hz, C5\u2032), 137.31, 130.26 (d, J = 7.9 Hz, C1\u2032), 129.72, 125.84, 123.80 diethyl trans5-[6-bromo-3-(4-fluorobenzyl)-4-oxo-3,4-dihydroquinazolin-2-yl]-2-methylisoxazolidin-3-ylphosphonate (trans-11h) found in yellowish oil. 3J(H4\u2013H5) = 6.4 Hz, 1H, HC4), 1.42 (t, 3J = 7.0 Hz, 3H, CH3CH2OP), 1.40 (t, 3J = 7.1 Hz, 3H, CH3CH2OP), 31P-NMR (151 MHz, CDCl3): = 22.00. diethyl trans-5-[6-bromo-3-(2,4-difluorobenzyl)-4-oxo-3,4-dihydroquinazolin-2-yl]-2-methylisoxazolidin-3-ylphosphonate (trans-11i) data presented below were extracted from a 92:8 mixture of trans-11i and cis-11i. 3J(H4\u2013H4) = 12.8 Hz, 3J(H4\u2013H3) = 9.7 Hz, 3J(H4\u2013H5) = 6.5 Hz, 1H, HC4), 1.41 (t, 3J = 7.0 Hz, 3H, CH3CH2OP), 1.40 (t, 3J = 7.0 Hz, 3H, CH3CH2OP), 1.40 (t, 3J = 7.0 Hz, 3H, CH3CH2 d, 2J(COP) = 6.5 Hz, CH2OP), 62.43 (d, 2J(CCCF) = 6.3 Hz, CH2OP), 46.57 (d, 3J(CNCP) = 4.0 Hz, CH3N), 37.89 (C4), 16.56 (d, 3J(CCOP) = 5.7 Hz, CH3CH2OP), 16.50 (d, 3J(CCOP) = 5.6 Hz, CH3CH ddd, 3J(H5\u2013H4) = 7.6 Hz, 3J(H5\u2013H4) = 5.7 Hz, 1H, HC5), 4.29\u20134.23 (m, 4H, 2 CH2OP), 3.75 (s, 3H, CH3), 3.71 (dddd, 3J(H4\u2013P) = 12.6 Hz, 2J(H4\u2013H4) = 11.3 Hz, 3J(H4\u2013H3) = 9. 1H-NMR (600 MHz, CDCl3): = 8.32 (d, 4J = 2.2 Hz, 1H, HC5\u2032), 7.90 (dd, 3J = 8.8 Hz, 4J = 2.2.Hz, 1H, HC7\u2032), 7.82 (d, 3J = 8.8 Hz, 4J = 2.2.Hz, 1H, HC7\u2032), 5.23 (dd, 3J = 8.8 Hz, 1H, 8.0 Hz, 3J(H5\u2013H4) = 6.0 Hz, 1H, HC5), 4.68 (q, 3J = 7.2 Hz, 2H, CH3CH2), 4.33\u20134.21 (m, 4H, 2 CH2OP), 3.45\u20133.43 (m, 1H, HC3), 3.07 (s, 3H, CH3N), 3.06\u20133.01 (m, 1H, HC3), 2.97 (dddd, antiviral activity assays were based on inhibition of virus-induced cytopathicity or plaque formation in human embryonic lung (HEL) fibroblasts, human epithelial cervix carcinoma cells (HeLa), Crandell-Rees feline kidney cells (CRFK), or Madin Darby canine kidney cells. the cell cultures were inoculated with 100 CCID50 of virus (1 CCID50 being the virus dose to infect 50% of the cell cultures) or with 20 plaque forming units (PFU) the cell cultures were incubated in the presence of varying concentrations of the test compounds. general 1H-NMR spectra were taken in CDCl3 on the following spectrometers. the IC50 was defined as the compound concentration required to inhibit cell proliferation by 50%. IR spectra were measured on an Infinity MI-60 FT-IR spectrometer. 2-(3-chloropropionylamino)benzamide (2.03 g, 6.63 mmol) in 5% sodium hydroxide (16.4 mL) and ethanol (8.2 mL) was stirred under reflux for 5 min. the crude 6-bromo-2-vinyl-3H-quinazolin-4(3H)-one was purified by crystallization from methanol. d, 4J = 8.7 Hz, 4J = 2.4 Hz, 1H, HC7), 7.90 (dd, 3J = 8.7 Hz, 1H, HC8), 6.63 (dd, 3J = 17.5 Hz, 2J = 3.7 Hz, 1H, CH=CH2), 6.53 (dd, 3J = 17.5 Hz, 3J = 8.1 Hz, 1H, CH=CH2), 5.86 (dd, an organic phase was dried (MgSO4), concentrated, and the crude product was purified on a silica gel column with a methylene chloride:hexane (7:3, v/v) mixture followed by crystallization (chloroform-petroleum ether or ethyl acetate) anal. Calcd. for C17H13BrN2O: C, 59.84; H, 3.84; N, 8.29. found: 6-Bromo-3-(2-nitrobenzyl)-2-vinylquinazolin-4(3H)-one (13c) 13C-NMR (151 MHz, CDCl3): = 164.62 (C=O), 160.12, 150.32, 147.84, 137.31, 136.31, 133.78, 132.33, 129.51, 129.05, 128.87, 125.76, 125.07, 120.38, 116.31, 65.14 (N-CH2). Hz, 2J = 1.4 Hz, 1H, CH=CH2), 5.84 (dd, 3J = 10.4 Hz, 2J = 1.4 Hz, 1H, CH=CH2), 5.78 (s, 2H, N-CH2). 13C-NMR (151 MHz, CDCl3): = 164.69 (C=O), 160.05, 150.49, 148.51, 138.14, 137.28, 136.68, 134 1H-NMR (600 MHz, CDCl3): = 8.31 (d, 4J = 2.2 Hz, 1H, HC5), 7.89 (dd, 3J = 8.9 Hz, 4J = 2.2 Hz, 1H, HC7), 7.68 (d, 3J = 8.9 Hz, 4J = 2.2 Hz, 1H, HC7), 7.42\u20137.38 (m, 1H), 7.42\u20137.38 (m, 1 dd, 3J = 17.2 Hz, 3J = 10.4 Hz, 1H, CH=CH2), 5.84 (dd, 3J = 10.4 Hz, 2J = 1.7 Hz, 1H, CH=CH2), 5.78 (s, 2H, N-CH2), 5.78 (s, 2H, N-CH2). 1H-NMR (600 MHz, CDCl3): = 8.32 (d, 4J = 2.2 Hz, 1H, HC5), 7.89 (dd, 3J = 8.9 Hz, 4J = 2.2 Hz, 1H, HC7), 7.43\u20137.39 (m, 1H), 7.34\u20137.32 (m, 1H), 7.28\u20137.26 (m, 1H), 7.11\u20137.08 (m, 1H), 6.92 (d d, 4J(CCCCF) = 3.1 Hz, C6\u2032, 120.18, 116.54, 115.33 (d, 2J(CCF) = 21.0 Hz, C4\u2032), 115.14 (d, 2J(CCF) = 22.0 Hz, C2\u2032), 67.77 (d, 4JCCCCF = 1.5 Hz, N-CH2), 5.82 (dd, 3J = 17.2 Hz, 3J = 13C-NMR (151 MHz, CDCl3): = 165.04 (C=O), 162.82 (d, 1J(CF) = 247.1 Hz, C4\u2032), 160.20, 150.40, 150.40, 150.40, 150.40, 137.04, 136.88, 131.84 (d, 4J(CCCCF) = 3.1 Hz, C1\u2032), 130.39 (d, 3J(CCCF) = 8.9 Hz, 4J = 2.1 Hz, 1H, HC7), 7.78 (d, 3J = 8.9 Hz, 1H, HC8), 7.59\u20137.55 (m, 1H), 6.96\u20136.89 (m, 2H), 6.89 (dd, 3J = 17.2 Hz, 3J = 10.0 Hz, 1H, CH=CH2), 6.72 (dd, 3J = 17.2 Hz, 2J = 2.4 the solution of 6-bromo-2-vinyl-3H-quinazolin-4-one was added. the solvent was removed and the residue was re-dissolved in methylene chloride (10 mL) and extracted with water (3 10 mL) 1H-NMR (200 MHz, CDCl3): = 8.21 (d, 4J = 2.1 Hz, 1H, HC5), 7.79 (dd, 3J = 8.9 Hz, 4J = 2.1 Hz, 1H, HC7), 7.67 (dd, 3J = 8.9 Hz, 1H, HC8), 6.83 (dd, 3J = 17.2 Hz, 3J = 9.9 Hz, 1H, CH= 1H-NMR (200 MHz, CDCl3): = 8.22 (d, 4J = 2.2 Hz, 1H, HC5), 7.79 (dd, 3J = 8.9 Hz, 4J = 2.2 Hz, 1H, HC7), 7.68 (dd, 3J = 8.9 Hz, 1H, HC8), 6.82 (dd, 3J = 17.2 Hz, 3J = 10.0 Hz, 1H, CH= crude products were subjected to chromatography on silica gel columns with chloroform:methanol (100:1, 50:1, 20:1, v/v) mixtures. diethyl trans-[5-(6-bromo-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylisoxazolidin-3-yl]phosphonate (trans-11a) 8.6 Hz, 3J(H4\u2013H3) = 8.3 Hz, 1H, HC4), 2.94 (ddd, 3J(H4\u2013H3) = 12.9 Hz, 3J(H4\u2013H3) = 10.0 Hz, 3J(H4\u2013H5) = 6.2 Hz, 1H, HC4), 1.40 (t, 3J = 7.1 Hz, 3H, CH3CH2OP), 1.38 (t, 3J = IR (film, cm1) max: 3090, 2959, 2925, 2865, 1661, 1626, 1601, 1461, 1336, 1234, 1054, 969, 834, 575. mo-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylisoxazolidin-3-yl]phosphonate (cis-11a) 3J(H4\u2013H3) = 9.6 Hz, 3J(H4\u2013H5) = 9.2 Hz, 1H, HC4), 1.32 (t, 3J = 7.0 Hz, 3H, 3H, CH3CH2OP), 1.27 (t, 3J = 7.1 Hz, 3H, CH3CH2OP), 31P-NMR (243 MHz, CDCl3): = 20.92. 1H-NMR (600 MHz, CDCl3): = 8.33 (d, 4J = 2.3 Hz, 1H, HC5\u2032), 7.90 (dd, 3J = 8.9 Hz, 4J = 2.3 Hz, 1H, HC7\u2032), 7.55\u20137.53 (m, 2H), 7.45\u20137.42 (m, 2H), 7.40\u20137.37 (m, 1H), 5.66 (dd, 3J = 6.8 1H-NMR (600 MHz, CDCl3): = 8.36 (d, 4J = 2.0 Hz, 1H, HC5\u2032), 8.20\u20138.18 (m, 1H), 7.95 (dd, 3J = 8.9 Hz, 4J = 2.3 Hz, HC7\u2032), 7.87 (dd, 3J = 8.9 Hz, 4J = 2.3 Hz, 1H, HC7\u2032). 4J = 8.9 Hz, 1H, HC8\u2032), 7.78\u20137.76 (m, 1H), 7.72\u20137.69 (m, 1H), 7.57\u20137.55 (m, 1H), 6.10 (AB, JAB = 14.6 Hz, 1H, N-CH2b), 6.07 (dd, 3J(H5\u2013H4) = 8.0 Hz, 3J(H5\u2013H4) = 6.1 Hz, 1H, HC4) d, 3J(CCCP) = 7.8 Hz, C5), 65.64 (N-CH2), 64.30 (d, 1J(CP) = 168.5 Hz, C3), 63.21 (d, 2J(COP) = 6.3 Hz, CH2OP), 46.61 (d, 3J(CNCP) = 4.2 Hz, CH3N) dd, 3J = 8.9 Hz, 4J = 2.0 Hz, 1H, HC7\u2032. 7.90\u20137.88 (m, 1H), 7.84 (d, 3J = 8.9 Hz, 1H, HC8\u2032), 7.63\u20137.60 (m, 1H), 5.77 (s, 2H, N-CH2), 5.29 (dd, 3J(H5\u2013H4) = 8.0 Hz, 3J(H5\u2013H 1H-NMR (600 MHz, CDCl3): = 8.35 (d, 4J = 2.0 Hz, 1H, HC5\u2032), 1H), 8.30\u20138.28 (m, 2H), 7.95 (dd, 3J = 8.9 Hz, 4J = 2.0 Hz, 1H, HC7\u2032), 7.72\u20137.71 (m, 2H), 5.76 (dd, 3J = 8.9 Hz, 1H, HC8\u2032 m, 1H, HC3), 3.07\u20132.98 (m, 1H, HC4), 3.03 (s, 3H, CH3-N), 2.94 (dddd, 3J(H4\u2013P) = 12.4 Hz, 2J(H4\u2013H4) = 12.4 Hz, 3J(H4\u2013H3) = 9.2 Hz, 3J(H4\u2013H5) = 6.0 Hz, 1H, HC4), 1.41 (t diethyl trans-5-[6-bromo-3-(2-fluorobenzyl)-4-oxo-3,4-dihydroquinazolin-2-yl]-2-methylisoxazolidin-3-ylphosphonate (trans-11f) data presented below were extracted from a 88:12 mixture of trans-11f and cis-11f. 3.42\u20133.39 (m, 1H, C3), 3.05 (s, 3H, CH3-N), 3.03\u20132.96 (m, 1H, HC4), 2.96 (dddd, 3J(H4\u2013P) = 12.5 Hz, 2J(H4\u2013H4) = 12.5 Hz, 3J(H4\u2013H3) = 8.9 Hz, 3J(H4\u2013H5) = 6.2 Hz, 1H, HC4), 1H-NMR (200 MHz, CDCl3): = 8.35\u20138.33 (m, 1H), 7.91\u20137.89 (m, 1H), 7.41\u20137.37 (m, 1H), 7.30\u20137.28 (m, 1H), 7.26\u20137.24 (m, 1H), 7.08\u20137.05 (m, 1H), 5.24 (dd, 3J(H5), 5.24 (dd, 3J(H5), 5.24 (dd \u2013H4) = 7.9 Hz, 3J(H5\u2013H4) = 6.5 Hz, 1H, HC5), 4.33\u20134.17 (m, 4H, 2 CH2OP), 3.05\u20132.99 (m, 1H, HC4), 2.95 (dddd, 3J(H4\u2013P) = 12.7 Hz, 2J(H4\u2013H4) = 12.7 Hz, 3J(H4\u2013H3) = 9.7 Hz, 3 d, 1J(CP) = 168.3 Hz, C3), 63.24 (d, 2J(COP) = 6.4 Hz, CH2OP), 46.57 (d, 3J(CNCP) = 3.7 Hz, CH3N), 37.84 (s, C4), 16.55 (d, 3J(CCOP) = 5.6 Hz, CH3CH2OP), 16.49 (d, 3J(CCOP) = 5.9 Hz, CH HC8\u2032), 7.55\u20137.53 (m, 2H), 7.14\u20137.11 (m, 2H), 5.63 (s, 1H, N-CH2), 5.26 (dd, 3J(H5\u2013H4) = 6.4 Hz, 3J(H5\u2013H4) = 6.4 Hz, 1H, HC5), 4.34\u20134.22 (m, 4H, 2 CH2OP), 3.41\u20133.39 (m, 1H, C3), 3.07 68.40 (N-CH2), 64.43 (d, 1J(CP) = 168.3 Hz, C3), 63.26 (d, 2J(COP) = 6.5 Hz, CH2OP), 46.59 (CH3N), 37.87 (C4), 16.56 (d, 3J(CCOP) = 5.8 Hz, CH3CH2OP), 16.46 (d, 3J(CCOP) = 5.3 Hz, CH3CH2 7.85 (d, 3J = 8.8 Hz, 1H, HC8\u2032), 7.59\u20137.55 (m, 1H), 6.95\u20136.89 (m, 2H), 5.68 (AB, JAB = 13.3 Hz, 1H, N-CH2a), 5.25 (dd, 3J(H5\u2013H4) = 7.7 Hz, 3J(H5\u2013H4) = 6.5 Hz, 1H, HC5), 4.33\u20134.18 ( Hz, 3J(CCCF) = 4.9 Hz, C6\u2032\u2032, 129.71, 125.87, 120.81, 118.98 (dd, 2J(CCF) = 14.4 Hz, 4J(CCCCF) = 3.4 Hz, C1\u2032\u2032), 116.58, 111.51 (dd, 2J(CCF) = 21.1 Hz, 4J(CCCCF) = 3.5 Hz, C5\u2032\u2032), 5-[6-bromo-3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]-2-methylisoxazolidin-3-ylphosphonate (trans-11j) IR (film, cm1) max: 3521, 3477, 2976, 2912, 2855, 1687, 1606, 1470, 1308, 1265, 1050, 1023, 1023, 849, 574. 15 Hz, 2J(H4\u2013H4) = 11.3 Hz, 3J(H4\u2013H3) = 7.6 Hz, 1H, HC4), 1.41 (t, 3J = 7.0 Hz, 3H, CH3CH2OP), 1.40 (t, 3J = 7.1 Hz, 3H, CH3CH2OP), 13C-NMR (151 MHz, CDCl3): = 161.31 (C=O), 152.70, 1H-NMR (600 MHz, CDCl3): = 8.32 (d, 4J = 2.2 Hz, 1H, HC5\u2032), 7.90 (dd, 3J = 8.8 Hz, 4J = 2.2.Hz, 1H, HC7\u2032), 7.82 (d, 3J = 8.8 Hz, 1H, HC8\u2032), 5.23 (dd, 3J = 8.0 Hz, 3J(H5\u2013H4) = 6.0 13C-NMR (151 MHz, CDCl3): =166.33 (C=O), 163.63, 149.78, 137.01, 129.63, 126.03, 120.47, 116.78, 80.22 (d, 3J(CCCP) = 7.9 Hz, C5), 64.38 (d, 1J(CP) = 168.0 Hz, C3), 63.28 (d, 2J(COP) = 6.4 sicular stomatitis virus, para-influenza-3 virus, reovirus-1, Sindbis virus, reovirus-1, Sindbis virus, respiratory syncytial virus (RSV), feline coronovirus (FIPV) and influenza A virus subtypes H1N1 (A/PR/8), H3N2 (A/HK/7/87) and influenza B virus (B/HK/5/72) the cytostatic concentration was calculated as the CC50, or the compound concentration required to reduce cell proliferation by 50%. the IC50 was defined as the compound concentration required to inhibit cell proliferation by 50%. almost all compounds were active against VZV and among them trans-11b, trans-11d, trans-11g, and trans-11h were the most potent (EC50 = 5.8\u201311.6 ) and, at the same time, exhibited lower cytotoxicity toward uninfected cell lines."}